What is the recommended target‑controlled infusion (TCI) protocol for remifentanil during anesthesia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Remifentanil TCI Infusion Protocol for Anaesthesia

For general anaesthesia maintenance, initiate remifentanil TCI at an effect-site target concentration of 3-5 ng/ml, with typical maintenance targets of 2-4 ng/ml depending on surgical stimulus and concurrent hypnotic depth. This dosing achieves drug administration consistent with FDA-approved recommendations of 0.25 μg/kg/min maintenance infusion rates 1.

Induction and Maintenance Dosing

Standard Adult Protocol

Induction:

  • Target effect-site concentration: 4 ng/ml achieves dosing equivalent to the FDA-recommended bolus of 0.5-1 μg/kg 1
  • This applies across the Minto, Eleveld, and Kim pharmacokinetic models with minor variations

Maintenance:

  • Standard target: 3-4 ng/ml (equivalent to 0.25 μg/kg/min infusion) 2, 1
  • Adjust in 0.5-1 ng/ml increments based on surgical stimulus and hypnotic depth
  • Maximum recommended: 5 ng/ml before risk of significant respiratory depression increases

Pediatric Dosing (Birth to 12 Years)

Continuous infusion: 0.05-0.3 μg/kg/min 3

  • Neonates and infants require lower end of range
  • Must be combined with appropriate hypnotic agent
  • Pretreatment with atropine recommended to prevent bradycardia 2

Specific Clinical Scenarios

At-Risk Extubation Protocol

When using remifentanil for smooth emergence in difficult airway cases 4:

  1. Before end of procedure: Set remifentanil at desired maintenance rate
  2. Discontinue hypnotic (propofol or volatile agent) while continuing remifentanil
  3. Continue ventilation until patient opens eyes to command
  4. Titrate down if spontaneous respiration inadequate (reduce by 25-50%)
  5. Discontinue immediately upon extubation and flush IV line thoroughly
  6. Critical warning: Post-extubation respiratory depression risk persists—close monitoring mandatory until fully recovered

Monitored Anaesthesia Care (MAC)

Single dose approach:

  • 0.5-1 μg/kg over 30-60 seconds, given 90 seconds before local anaesthetic placement 2

Continuous infusion approach:

  • Initial target: 1-2 ng/ml for conscious sedation 5, 6
  • Optimal target: 3 ng/ml provides effective sedation without significant respiratory depression during spinal anaesthesia 5
  • Higher targets (3.5 ng/ml) significantly increase respiratory depression and PONV without additional benefit 5
  • For cataract surgery with propofol TCI (1 μg/ml): remifentanil target of 1 ng/ml provides optimal patient and surgeon satisfaction 6

Awake Fiberoptic Intubation

Effect-site target: 0.8 ng/ml provides superior conditions compared to manual infusion 7

  • More stable vital signs
  • Less recall and pain
  • Shorter preparation time
  • Better sedation quality

Postoperative Analgesia Continuation

Only under direct anesthesia practitioner supervision 2:

  • Initial rate: 0.1 μg/kg/min (approximately 1.5-2 ng/ml target)
  • Adjust by 0.025 μg/kg/min increments every 5 minutes
  • Maximum: 0.2 μg/kg/min (respiratory rate <8/min beyond this)
  • Critical: Transition to longer-acting analgesics before discontinuation—remifentanil provides NO residual analgesia within 5-10 minutes of stopping 2

Age-Specific Modifications

Geriatric Patients (>65 Years)

Reduce all starting doses by 50% 2:

  • Induction target: 2 ng/ml (not 4 ng/ml)
  • Maintenance target: 2 ng/ml (not 4 ng/ml)
  • Titrate cautiously upward based on response
  • Effect-site targeting requires even lower targets due to increased sensitivity

Obese Patients

Use lean body weight for dosing calculations 8

  • Plasma targets of 3-5 ng/ml remain appropriate 1
  • Standard TCI models (Minto, Eleveld) account for obesity when programmed correctly

Critical Safety Considerations

Respiratory Depression Management

Muscle rigidity and chest wall rigidity occur with:

  • Single doses >1 μg/kg over 30-60 seconds
  • Infusion rates >0.1 μg/kg/min
  • Any bolus when combined with continuous infusion 2

Management:

  • Immediate neuromuscular blockade for life-threatening rigidity
  • Reduce or stop infusion for spontaneously breathing patients
  • Naloxone as rescue (but eliminates all analgesia)
  • Resolution occurs within minutes of stopping infusion

Mandatory Monitoring

  • Continuous capnography until airway device removed and verbal response established 9
  • Pulse oximetry, ECG, blood pressure throughout
  • Respiratory rate monitoring critical—depression occurs before desaturation 10, 11

IV Line Management

Flush IV tubing thoroughly after discontinuation 2:

  • Residual remifentanil causes delayed respiratory depression, apnea, and muscle rigidity when other fluids administered through same line
  • This is a frequently reported complication
  • Use dedicated IV line when possible

Drug Interactions

Avoid bolus dosing when combining with:

  • Benzodiazepines (start at lowest effective dose) 2
  • Other CNS depressants
  • Serotonergic drugs (risk of serotonin syndrome) 2

Never administer into same IV line as blood products—nonspecific esterases inactivate remifentanil 2

Practical TCI Model Selection

All three validated models (Minto, Eleveld, Kim) produce similar clinical results when targeting plasma concentrations of 3-5 ng/ml for initial dosing 1. The Minto model remains most widely validated across age ranges and clinical scenarios.

Effect-site targeting provides smoother titration but requires understanding of ke0 (effect-site equilibration) for each model—typically 1-2 minutes for remifentanil.

References

Related Questions

What target‑controlled infusion (TCI) effect‑site concentrations of remifentanil are recommended for anesthesia, sedation, awake fiberoptic intubation, and spinal procedures in adult ASA I‑III patients?
What is the recommended initial effect-site concentration and titration protocol for Remifentanyl (generic name: Remifentanil) using a Target-Controlled Infusion (TCI) model?
What target‑controlled infusion remifentanil concentration and midazolam bolus dose should I use for a 68‑year‑old woman with recent myocardial infarction, chronic kidney disease, and diabetes?
What initial target‑controlled infusion (TCI) effect‑site concentrations of propofol and remifentanil should be used for a 68‑year‑old woman, 59 kg, 152 cm, with an ejection fraction of 47 % undergoing coronary angiography?
What is the recommended approach for managing Target Controlled Infusion (TCI) in anesthesia?
What are the mechanisms, recommended dosing, and target‑controlled infusion (TCI) parameters for opioids in anesthesia, acute postoperative pain, and chronic pain management?
In a 60-year-old woman with recent antibiotic treatment for a urinary tract infection, on methotrexate for rheumatoid arthritis and warfarin for atrial fibrillation, presenting with a week of increasing watery non‑bloody diarrhea, lower abdominal cramping, mild diffuse tenderness, anemia, leukocytosis, impaired renal function, and elevated C‑reactive protein, which diagnosis is most likely: ischemic colitis, inflammatory bowel disease, microscopic colitis, or Clostridioides difficile colitis?
What is the appropriate management and evaluation strategy for chronic pyelonephritis with urine cultures persistently growing multidrug‑resistant Klebsiella pneumoniae that is only susceptible to tigecycline and colistin?
In a 61-year-old man with restless‑leg syndrome, daytime sleepiness (Epworth Sleepiness Scale score 12), BMI 28, baseline serum ferritin 30 ng/mL, periodic limb movement index 45/hr, who has been started on iron therapy, which of the following findings indicates that iron supplementation should be discontinued: serum ferritin 50 ng/mL, total iron‑binding capacity 300 µg/dL, hemoglobin 13.5 g/dL, or transferrin saturation 50%?
Should valsartan (angiotensin II receptor blocker) be given only once daily, is nebivolol (beta‑blocker) needed to keep heart rate below 100 beats per minute, and can amlodipine besylate (amlodipine) be taken twice daily at 5 mg?
What is the recommended regimen, safety considerations, and contraindications for using tropicamide and phenylephrine together for pupil dilation in eye examinations?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.